Show simple item record

dc.contributor.authorAndrade, Susan E.
dc.contributor.authorRaebel, Marsha A.
dc.contributor.authorBrown, Jeffrey S.
dc.contributor.authorLane, Kimberly
dc.contributor.authorLivingston, James
dc.contributor.authorBoudreau, Denise M.
dc.contributor.authorRolnick, Sharon J.
dc.contributor.authorRoblin, Douglas W.
dc.contributor.authorSmith, David H.
dc.contributor.authorDal Pan, Gerald J.
dc.contributor.authorScott, Pamela E.
dc.contributor.authorPlatt, Richard
dc.date2022-08-11T08:09:22.000
dc.date.accessioned2022-08-23T16:28:31Z
dc.date.available2022-08-23T16:28:31Z
dc.date.issued2008-03-18
dc.date.submitted2011-12-30
dc.identifier.citationPharmacoepidemiol Drug Saf. 2008 Mar;17(3):240-7. <a href="http://dx.doi.org/10.1002/pds.1550">Link to article on publisher's site</a>
dc.identifier.issn1053-8569 (Linking)
dc.identifier.doi10.1002/pds.1550
dc.identifier.pmid18200619
dc.identifier.urihttp://hdl.handle.net/20.500.14038/37035
dc.description.abstractPURPOSE: To provide information on the prevalence of use of cardiovascular drugs, some of which may have fetotoxic or teratogenic effects, in the outpatient setting among pregnant women in the United States. METHODS: A retrospective study was conducted using the automated databases of seven health plans participating in the HMO Research Network Center for Education and Research on Therapeutics (CERT). Women who delivered an infant from 1 January 2001 to 31 December 2005 were identified. Cardiovascular drug use was evaluated assuming a gestational duration of 270 days. RESULTS: During the period 2001 through 2005, 118,935 deliveries were identified that met the criteria for study; 3.1% of women (N = 3672) were dispensed an antihypertensive medication and 0.12% of women (N = 146) were dispensed an antihyperlipidemic medication at any time during pregnancy. The most common antihypertensive drugs dispensed during pregnancy were nifedipine (1219 deliveries; 1.0%), methyldopa (961 deliveries; 0.8%), atenolol (593 deliveries; 0.5%), and labetalol (576 deliveries; 0.5%). Overall, 134 women (0.11%) received an angiotensin converting enzyme (ACE) inhibitor and 7 women (0.006%) received an angiotensin II receptor blocker (ARB) during pregnancy. Statins were the most commonly dispensed antihyperlipidemic drugs (71 deliveries; 0.06%). CONCLUSIONS: The prevalence of use of cardiovascular drugs that are suspected to be fetotoxic or teratogenic (ACE inhibitors, ARBs, and statins) was low in this cohort of pregnant women. Differing patterns of use across health plans suggests that further research is needed to evaluate the potential differential effects of cardiovascular drugs to assist prescribers and patients in making informed treatment decisions.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=18200619&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/pds.1550
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAngiotensin II Type 1 Receptor Blockers
dc.subjectAngiotensin-Converting Enzyme Inhibitors
dc.subjectAntihypertensive Agents
dc.subjectCardiovascular Agents
dc.subjectDatabases, Factual
dc.subjectFemale
dc.subjectHealth Maintenance Organizations
dc.subjectHumans
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors
dc.subjectuse
dc.subjectHypolipidemic Agents
dc.subjectMiddle Aged
dc.subjectOutpatients
dc.subjectPregnancy
dc.subjectPregnancy Complications, Cardiovascular
dc.subjectPrevalence
dc.subjectRetrospective Studies
dc.subjectTeratogens
dc.subjectUnited States
dc.subjectHealth Services Research
dc.subjectMaternal and Child Health
dc.subjectPrimary Care
dc.titleOutpatient use of cardiovascular drugs during pregnancy
dc.typeJournal Article
dc.source.journaltitlePharmacoepidemiology and drug safety
dc.source.volume17
dc.source.issue3
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/meyers_pp/421
dc.identifier.contextkey2426077
html.description.abstract<p>PURPOSE: To provide information on the prevalence of use of cardiovascular drugs, some of which may have fetotoxic or teratogenic effects, in the outpatient setting among pregnant women in the United States.</p> <p>METHODS: A retrospective study was conducted using the automated databases of seven health plans participating in the HMO Research Network Center for Education and Research on Therapeutics (CERT). Women who delivered an infant from 1 January 2001 to 31 December 2005 were identified. Cardiovascular drug use was evaluated assuming a gestational duration of 270 days.</p> <p>RESULTS: During the period 2001 through 2005, 118,935 deliveries were identified that met the criteria for study; 3.1% of women (N = 3672) were dispensed an antihypertensive medication and 0.12% of women (N = 146) were dispensed an antihyperlipidemic medication at any time during pregnancy. The most common antihypertensive drugs dispensed during pregnancy were nifedipine (1219 deliveries; 1.0%), methyldopa (961 deliveries; 0.8%), atenolol (593 deliveries; 0.5%), and labetalol (576 deliveries; 0.5%). Overall, 134 women (0.11%) received an angiotensin converting enzyme (ACE) inhibitor and 7 women (0.006%) received an angiotensin II receptor blocker (ARB) during pregnancy. Statins were the most commonly dispensed antihyperlipidemic drugs (71 deliveries; 0.06%).</p> <p>CONCLUSIONS: The prevalence of use of cardiovascular drugs that are suspected to be fetotoxic or teratogenic (ACE inhibitors, ARBs, and statins) was low in this cohort of pregnant women. Differing patterns of use across health plans suggests that further research is needed to evaluate the potential differential effects of cardiovascular drugs to assist prescribers and patients in making informed treatment decisions.</p>
dc.identifier.submissionpathmeyers_pp/421
dc.contributor.departmentMeyers Primary Care Institute
dc.source.pages240-7


This item appears in the following Collection(s)

Show simple item record